Update shared on14 Sep 2025
Fair value Increased 2.14%The recent upward revision in Everest Medicines’ consensus Analyst Price Target is primarily driven by a modest increase in its expected future P/E multiple, lifting fair value from HK$61.36 to HK$62.67.
What's in the News
- Everest Medicines expects 2025 revenue of RMB 1.6–1.8 billion, with NEFECON sales contributing RMB 1.2–1.4 billion.
- Board meeting scheduled to discuss interim results for the six months ended June 30, 2025.
- Completed a follow-on equity offering, raising HKD 1.57 billion with 22,561,000 ordinary shares at HKD 69.7 per share via direct listing.
- Certain ordinary shares are subject to a 91-day lock-up period ending October 31, 2025, restricting sales without placement agent consent.
Valuation Changes
Summary of Valuation Changes for Everest Medicines
- The Consensus Analyst Price Target has risen slightly from HK$61.36 to HK$62.67.
- The Future P/E for Everest Medicines has risen slightly from 32.14x to 33.36x.
- The Net Profit Margin for Everest Medicines remained effectively unchanged, moving only marginally from 21.23% to 21.17%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.